Anaplastic Lymphoma Kinase (ALK) Positive - Epidemiology Forecast to 2032

January 2022 | 60 pages | ID: AD024DF44E09EN
DelveInsight

Abstracts

This report can be delivered to the clients within 5-7 Business Days

DelveInsight's 'Anaplastic Lymphoma Kinase (ALK) Positive - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Anaplastic Lymphoma Kinase (ALK) Positive epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2019-2032

Anaplastic Lymphoma Kinase (ALK) Positive Understanding

The DelveInsight Anaplastic Lymphoma Kinase (ALK) Positive epidemiology report gives a thorough understanding of the Anaplastic Lymphoma Kinase (ALK) Positive by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Anaplastic Lymphoma Kinase (ALK) Positive in the US, Europe, and Japan. The report covers the detailed information of the Anaplastic Lymphoma Kinase (ALK) Positive epidemiology scenario in seven major countries (US, EU5, and Japan).

Anaplastic Lymphoma Kinase (ALK) Positive Epidemiology Perspective by DelveInsight

The Anaplastic Lymphoma Kinase (ALK) Positive epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Anaplastic Lymphoma Kinase (ALK) Positive epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Anaplastic Lymphoma Kinase (ALK) Positive epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2019 to 2032. It also helps recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Anaplastic Lymphoma Kinase (ALK) Positive Detailed Epidemiology Segmentation

The Anaplastic Lymphoma Kinase (ALK) Positive epidemiology covered in the report provides historical as well as forecasted Anaplastic Lymphoma Kinase (ALK) Positive epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

The DelveInsight Anaplastic Lymphoma Kinase (ALK) Positive report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report

• The Anaplastic Lymphoma Kinase (ALK) Positive report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The Anaplastic Lymphoma Kinase (ALK) Positive Epidemiology Report and Model provide an overview of the global trends of Anaplastic Lymphoma Kinase (ALK) Positive in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
• The report provides insight into the historical and forecasted patient pool of Anaplastic Lymphoma Kinase (ALK) Positive in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
• The report helps recognize the growth opportunities in the 7MM for the patient population
• The report assesses the disease risk and burden and highlights the unmet needs of Anaplastic Lymphoma Kinase (ALK) Positive
• The report provides the segmentation of the Anaplastic Lymphoma Kinase (ALK) Positive epidemiology

Report Highlights

• 11-year Forecast of Anaplastic Lymphoma Kinase (ALK) Positive epidemiology
• 7MM Coverage
• Prevalent and Diagnosed Cases of Anaplastic Lymphoma Kinase (ALK) Positive
• Cases of Anaplastic Lymphoma Kinase (ALK) Positive by Mutation Types
• Anaplastic Lymphoma Kinase (ALK) Positive Cases associated with Clinical Manifestations

KOL views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Anaplastic Lymphoma Kinase (ALK) Positive?
• What are the key findings pertaining to the Anaplastic Lymphoma Kinase (ALK) Positive epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2019-2032)?
• What would be the total number of patients of Anaplastic Lymphoma Kinase (ALK) Positive across the 7MM during the forecast period (2019-2032)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2019-2032)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?
• What is the disease risk, burden and unmet needs of Anaplastic Lymphoma Kinase (ALK) Positive?
• What are the currently available treatments of Anaplastic Lymphoma Kinase (ALK) Positive?

Reasons to buy

The Anaplastic Lymphoma Kinase (ALK) Positive Epidemiology report will allow the user to -

• Develop business strategies by understanding the trends shaping and driving the global Anaplastic Lymphoma Kinase (ALK) Positive market
• Quantify patient populations in the global Anaplastic Lymphoma Kinase (ALK) Positive market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Anaplastic Lymphoma Kinase (ALK) Positive therapeutics in each of the markets covered
• Understand the magnitude of Anaplastic Lymphoma Kinase (ALK) Positive population by its epidemiology
• The Anaplastic Lymphoma Kinase (ALK) Positive Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

• Patient Segmentation
• Disease Risk & Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Contents

1. KEY INSIGHTS

2. EXECUTIVE SUMMARY OF ANAPLASTIC LYMPHOMA KINASE (ALK) POSITIVE

3. ANAPLASTIC LYMPHOMA KINASE (ALK) POSITIVE: DISEASE BACKGROUND AND OVERVIEW

3.1. Introduction
3.2. Sign and Symptoms
3.3. Pathophysiology
3.4. Risk Factors
3.5. Diagnosis

4. PATIENT JOURNEY

5. EPIDEMIOLOGY AND PATIENT POPULATION

5.1. Epidemiology Key Findings
5.2. Assumptions and Rationale: 7MM
5.3. Epidemiology Scenario: 7MM
  5.3.1. Anaplastic Lymphoma Kinase (ALK) Positive Epidemiology Scenario in the 7MM (2019- 2032)
5.4. United States Epidemiology
  5.4.1. Anaplastic Lymphoma Kinase (ALK) Positive Epidemiology Scenario in the United States (2019- 2032)
5.5. EU-5 Country-wise Epidemiology
  5.5.1. Germany Epidemiology
    5.5.1.1. Anaplastic Lymphoma Kinase (ALK) Positive Epidemiology Scenario in Germany (2019- 2032)
  5.5.2. France Epidemiology
    5.5.2.1. Anaplastic Lymphoma Kinase (ALK) Positive Epidemiology Scenario in France (2019- 2032)
  5.5.3. Italy Epidemiology
    5.5.3.1. Anaplastic Lymphoma Kinase (ALK) Positive Epidemiology Scenario in Italy (2019- 2032)
  5.5.4. Spain Epidemiology
    5.5.4.1. Anaplastic Lymphoma Kinase (ALK) Positive Epidemiology Scenario in Spain (2019- 2032)
  5.5.5. United Kingdom Epidemiology
    5.5.5.1. Anaplastic Lymphoma Kinase (ALK) Positive Epidemiology Scenario in the United Kingdom (2019-2032)
5.6. Japan Epidemiology
  5.6.1. Anaplastic Lymphoma Kinase (ALK) Positive Epidemiology Scenario in Japan (2019- 2032)

6. TREATMENT ALGORITHM, CURRENT TREATMENT, AND MEDICAL PRACTICES

6.1. Anaplastic Lymphoma Kinase (ALK) Positive Treatment and Management
6.2. Anaplastic Lymphoma Kinase (ALK) Positive Treatment Algorithm

7. KOL VIEWS

8. UNMET NEEDS

9. APPENDIX

9.1. Bibliography
9.2. Report Methodology

10. DELVEINSIGHT CAPABILITIES

11. DISCLAIMER

12. ABOUT DELVEINSIGHT

*The table of contents is not exhaustive; will be provided in the final report

List Of Tables

LIST OF TABLES

List of Table:
Table 1: Anaplastic Lymphoma Kinase (ALK) Positive Epidemiology in 7MM (2019-2032)
Table 2: Anaplastic Lymphoma Kinase (ALK) Positive Diagnosed and Treatable Cases in 7MM (2019-2032)
Table 3: Anaplastic Lymphoma Kinase (ALK) Positive Epidemiology in the United States (2019-2032)
Table 4: Anaplastic Lymphoma Kinase (ALK) Positive Diagnosed and Treatable Cases in the United States (2019-2032)
Table 5: Anaplastic Lymphoma Kinase (ALK) Positive Epidemiology in Germany (2019-2032)
Table 6: Anaplastic Lymphoma Kinase (ALK) Positive Diagnosed and Treatable Cases in Germany (2019-2032)
Table 7: Anaplastic Lymphoma Kinase (ALK) Positive Epidemiology in France (2019-2032)
Table 8: Anaplastic Lymphoma Kinase (ALK) Positive Diagnosed and Treatable Cases in France (2019-2032)
Table 9: Anaplastic Lymphoma Kinase (ALK) Positive Epidemiology in Italy (2019-2032)
Table 10: Anaplastic Lymphoma Kinase (ALK) Positive Diagnosed and Treatable Cases in Italy (2019-2032)
Table 11: Anaplastic Lymphoma Kinase (ALK) Positive Epidemiology in Spain (2019-2032)
Table 12: Anaplastic Lymphoma Kinase (ALK) Positive Diagnosed and Treatable Cases in Spain (2019-2032)
Table 13: Anaplastic Lymphoma Kinase (ALK) Positive Epidemiology in the United Kingdom (2019-2032)
Table 14: Anaplastic Lymphoma Kinase (ALK) Positive Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Table 15: Anaplastic Lymphoma Kinase (ALK) Positive Epidemiology in Japan (2019-2032)
Table 16: Anaplastic Lymphoma Kinase (ALK) Positive Diagnosed and Treatable Cases in Japan (2019-2032)

List Of Figures

LIST OF FIGURES

List of Figures
Figure 1 Anaplastic Lymphoma Kinase (ALK) Positive Epidemiology in 7MM (2019-2032)
Figure 2 Anaplastic Lymphoma Kinase (ALK) Positive Diagnosed and Treatable Cases in 7MM (2019-2032)
Figure 3 Anaplastic Lymphoma Kinase (ALK) Positive Epidemiology in the United States (2019-2032)
Figure 4 Anaplastic Lymphoma Kinase (ALK) Positive Diagnosed and Treatable Cases in the United States (2019-2032)
Figure 5 Anaplastic Lymphoma Kinase (ALK) Positive Epidemiology in Germany (2019-2032)
Figure 6 Anaplastic Lymphoma Kinase (ALK) Positive Diagnosed and Treatable Cases in Germany (2019-2032)
Figure 7 Anaplastic Lymphoma Kinase (ALK) Positive Epidemiology in France (2019-2032)
Figure 8 Anaplastic Lymphoma Kinase (ALK) Positive Diagnosed and Treatable Cases in France (2019-2032)
Figure 9 Anaplastic Lymphoma Kinase (ALK) Positive Epidemiology in Italy (2019-2032)
Figure 10 Anaplastic Lymphoma Kinase (ALK) Positive Diagnosed and Treatable Cases in Italy (2019-2032)
Figure 11 Anaplastic Lymphoma Kinase (ALK) Positive Epidemiology in Spain (2019-2032)
Figure 12 Anaplastic Lymphoma Kinase (ALK) Positive Diagnosed and Treatable Cases in Spain (2019-2032)
Figure 13 Anaplastic Lymphoma Kinase (ALK) Positive Epidemiology in the United Kingdom (2019-2032)
Figure 14 Anaplastic Lymphoma Kinase (ALK) Positive Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Figure 15 Anaplastic Lymphoma Kinase (ALK) Positive Epidemiology in Japan (2019-2032)
Figure 16 Anaplastic Lymphoma Kinase (ALK) Positive Diagnosed and Treatable Cases in Japan (2019-2032)
*The table of contents is not exhaustive; will be provided in the final report